Department of Medicine, Division of Translational Research and Clinical Epidemiology, Wayne State University, Detroit, MI 48201, USA.
Curr Cardiol Rep. 2012 Dec;14(6):660-6. doi: 10.1007/s11886-012-0314-6.
African Americans manifest an inordinately high burden of hypertension, pressure-related target-organ injury (eg, left ventricular hypertrophy, stroke), and sub-optimal hypertension control rates to conventional levels (<140/90 mm Hg). A substantive proportion of the excessive premature mortality in African Americans relative to Whites is pressure-related. Randomized prospective pharmacologic hypertension end-point trials have shown invariable cardiovascular disease (CVD) risk reduction across a broad range of pre-treatment BP levels down to 110/70 mm Hg with the magnitude of CVD risk reduction across the 5 major antihypertensive drug classes being directly linked to degree of blood pressure (BP) lowering. Pooled endpoint data from pharmacologic hypertension trials in African Americans showed that CVD risk reduction was the same with major antihypertensive drug classes when similar levels of BP were achieved. A lower than conventional BP target for African Americans seems justified and prudent because attainment of lower BP should incrementally lower CVD risk in this high-risk population.
非裔美国人表现出高血压、与压力相关的靶器官损伤(如左心室肥厚、中风)以及血压控制率不理想(未达到<140/90 mmHg)的极高负担。相对于白人,非裔美国人的过早死亡率过高,其中相当一部分与血压有关。随机前瞻性药物治疗高血压终点试验表明,在广泛的治疗前血压水平范围内(降至 110/70 mmHg),心血管疾病(CVD)风险始终降低,5 大降压药物类别降低 CVD 的风险幅度与血压降低的幅度直接相关。非裔美国人药物治疗高血压试验的汇总终点数据显示,当达到相似的血压水平时,主要降压药物类别对 CVD 风险的降低效果相同。对于非裔美国人来说,设定低于传统的血压目标似乎是合理和谨慎的,因为在这个高危人群中,降低血压应该会逐渐降低 CVD 风险。